This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Resources

Kerendia®▼ (finerenone) and the Kidneys

Breaking Barriers in CKD Management

Kerendia

Welcome to our

Kerendia and the Kidneys - Breaking Barriers in CKD Management
short video series. 

Kidney expert

Dr Albert Power
covers critical areas in the management in your CKD patients: 

  • Part One | Diagnosing and understanding the risks of CKD.
  • Part Two | Optimising management in CKD in T2D.
  • Part Three | What is Kerendia and why should we prescribe it?
  • Part Four | What Is the profile of a potential Kerendia patient?
  • Part Five | Prescribing Kerendia: Initiation, continuation and hyperkalaemia management.

These concise sessions are packed with insights relevant to

both primary and secondary care.
 

We would love to hear your feedback on these videos to help us shape future resources for the future- feedback form

Diagnosing and understanding the risks of CKD (4:07 min)

Prescribing information for Kerendia®▼(finerenone) can be found here.

CKD=chronic kidney disease; MOD=mechanism of disease; MOA=mechanism of action.

PP-KER-GB-0798 | February 2025

Related Content

Kerendia®▼ (finerenone) Primary Care Resources
Access useful, downloadable nephrology resources for HCPs in primary care.
RP-KER-GB-1106, February 2025